Government urged to buy ‘game changer’ Covid-19 drug treatment | RNZ News

Generally the monoclonal antibodies (Mabs) are not required for healthy people who are not at added risk of serious illness from Covid-19. They are targeted towards older people or those with other added risk factors, such as asthma, kidney or lung disease, obesity or diabetes.

Australia approved one of them, Sotrovimab, and had it in the country ready to use in mid-August.

“The sotrovimab treatment requires a single dose to be administered through an intravenous (IV) infusion in a health care facility and has been shown to reduce hospitalisation or death by 79 percent in adults with mild to moderate Covid-19, who are at risk of developing severe Covid-19,” Health Minister Greg Hunt said.

Source: Government urged to buy ‘game changer’ Covid-19 drug treatment | RNZ News